Home » Nipah virus, good results of the new vaccine in animal testing

Nipah virus, good results of the new vaccine in animal testing

by admin
Nipah virus, good results of the new vaccine in animal testing

A new mucosal vaccine has prevented infection from virus Nipah in hamsters and mice. This is demonstrated by the study of Centers for Disease Control and Prevention, published in Science Advances. Researchers developed a one-dose intranasal vaccine that prevents Nipah virus infection in hamsters and mice as early as three days after administration.

Twenty dangerous viruses under special surveillance: the threat of new pandemics by Donatella Zorzetto 06 June 2023

The new replicon-particle vaccine could be a significant step forward in efforts to protect against virus Nipaha disease that can be fatal, considered one emerging threat to public health due to its high mortality rates and its ability to transfer between multiple species.

The disease triggered by the Nipah virus

NiV is a bat-borne disease that is spread through direct contact with infected animals and their bodily fluids. The virus can cause severe respiratory and neurological symptoms leading to death in 80% of cases. Outbreaks have so far been limited to regions of South and Southeast Asia, mainly India and Bangladesh. However, interspecific transmission has raised concerns for the potential spread of the virus globally.

Nipah virus kills 12-year-old boy in India: health alert in Kerala. What it is and how it manifests itself 07 September 2021

The principle of the new vaccine

Most NiV vaccine candidates are still in preclinical development, and few studies have explored vaccines that use replicons, virus-like particles engineered without certain genes to trigger an immune response without causing infection.

Not, Stephen Welch, together with colleagues at the Centers for Disease Control and Prevention, has developed a replicon-particle vaccine for NiV that lacks the fusion protein gene, which the virus needs to infect cells; the vaccine prevented NiV infections in hamsters and suckling mice as early as three days after administration. Mucosal vaccine in hamsters and mice elicited a strong antibody response, demonstrating high safety and protective efficacy against NiV infections.

“The platform composed of viral replicon particles represents an extremely beneficial tool for the field of henipavirusparticularly as it can be used at lower containment levels,” the authors said.

See also  Not everyone drinks it but this concentrate keeps blood sugar at bay and fights Alzheimer's

What if the elixir of life was in bats? by Roberta Villa March 24, 2023 Topics

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy